希維奧®預計2022銷售額將達1.8億-2億元人民幣
格隆匯12月20日|德琪醫藥-B(6996.HK)創始人、董事長兼首席執行官梅建明博士在希維奧®產品獲批投資人電話會上表示,希維奧®在中國大陸市場,預計在2022年Q2正式開始商業化銷售。
基於希維奧®與多個藥物的聯用潛力,預計2022年銷售額將達到1.8億元-2億元。目前其在中國的商業團隊約150人,覆蓋了中國血液腫瘤領域的前200家醫院,後續將擴展到400-500家,覆蓋所有含有血液科的醫院。同時,在亞太其他市場,希維奧®預計在2022年-2023年進入全民健康保險後,正式開始商業化。
產品正式銷售後,德琪醫藥將開始產生收入,現有資金和後續的經營性現金流將有效支撐公司創新管線的推進,預計2022年將有多款臨牀階段的產品會披露數據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.